NASDAQ · MRNAHealthcareBiotechnology

Moderna financials

$203.46+3.13%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
FY20
Dec 31
FY19
Dec 31
FY18
Dec 31
Revenue$1.94B$3.24B$6.85B$19.26B$18.47B$803.0M$60.0M$135.1M
Gross profit$1.08B$1.77B$2.15B$13.85B$15.85B$795.0M$60.0M$135.1M
Gross margin55.3%54.8%31.5%71.9%85.8%99.0%100.0%100.0%
Operating income-$3.07B-$3.94B-$4.24B$9.42B$13.30B-$763.0M-$546.0M-$413.3M
Net income-$2.82B-$3.56B-$4.71B$8.36B$12.20B-$747.0M-$514.0M-$401.9M
Net margin−145.2%−110.0%−68.8%43.4%66.1%−93.0%−856.7%−297.5%
Diluted EPS$-7.26$-9.28$-12.33$20.12$28.29$-1.96$-1.55$-4.95
EBITDA-$2.86B-$3.76B-$3.62B$9.77B$13.53B-$732.0M-$515.0M-$388.4M
Operating cash flow-$1.87B-$3.00B-$3.12B$4.98B$13.62B$2.03B-$459.0M-$330.9M
Free cash flow-$2.06B-$4.05B-$3.83B$4.58B$13.34B$1.96B-$491.0M-$436.6M
Diluted shares389.0M384.0M382.0M416.0M431.0M381.0M331.0M81.1M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$2.60B$1.93B$2.91B$3.21B$6.85B$2.62B
Short-term investments$3.20B$5.10B$5.70B$6.70B$3.88B$1.98B
Total debt$610.0M$39.0M$575.0M$912.0M$599.0M$110.0M
Total assets$12.34B$14.14B$18.43B$25.86B$24.67B$7.34B
Total liabilities$3.69B$3.24B$4.57B$6.74B$10.52B$4.78B
Shareholders' equity$8.65B$10.90B$13.85B$19.12B$14.14B$2.56B

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology